Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vixotrigine - Biogen

Drug Profile

Vixotrigine - Biogen

Alternative Names: 1014802; BIIB 074; CNV 1014802; CNV 1014802 A; GSK 1014802 A; GSK1014802; Raxatrigine

Latest Information Update: 08 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Biogen; GlaxoSmithKline
  • Class Analgesics; Neuropsychotherapeutics; Pyrrolidines; Small molecules
  • Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Trigeminal neuralgia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Neuropathic pain; Trigeminal neuralgia

Highest Development Phases

  • Phase III Trigeminal neuralgia
  • Phase II Erythromelalgia; Neuropathic pain
  • Discontinued Bipolar disorders; Sciatica

Most Recent Events

  • 26 Sep 2019 Biogen plans a phase I trial for painful Diabetic neuropathies (PO) in November 2019 (NCT04106050)
  • 07 Feb 2019 Discontinued - Phase-II for Sciatica in Estonia, Netherlands, Serbia, Belgium, Romania, Italy, Georgia, United Kingdom, Bulgaria, Austria, Austria, Spain, Slovakia, Latvia, France, Czech Republic, Denmark, Sweden (PO) (NCT02957617)
  • 06 Aug 2018 Biogen completes a phase II trial in Sciatica in Austria, Belgium, Bulgaria, Czech Republic, Denmark, England, Estonia, Finland, France, Georgia, Italy, Latvia, Lithuania, Netherlands, Poland, Romania, Scotland, Serbia, Slovakia, Spain, United Kingdom (PO) (NCT02935608; EudraCT2015-004775-78)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top